GVHD - GRAFT-VERSUS-HOST DISEASE
Clinical trials for GVHD - GRAFT-VERSUS-HOST DISEASE explained in plain language.
Never miss a new study
Get alerted when new GVHD - GRAFT-VERSUS-HOST DISEASE trials appear
Sign up with your email to follow new studies for GVHD - GRAFT-VERSUS-HOST DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for transplant patients with life-threatening immune attack
Disease control Not yet recruitingThis study tests whether adding a special cell therapy (remestemcel-L) to standard treatment (ruxolitinib) can help adults with severe graft-versus-host disease (GVHD) that hasn't responded to steroids. GVHD is a serious complication where donor immune cells attack the patient's …
Matched conditions: GVHD - GRAFT-VERSUS-HOST DISEASE
Phase: PHASE3 • Sponsor: Mesoblast, Ltd. • Aim: Disease control
Last updated May 17, 2026 03:39 UTC
-
Could a lower drug dose make stem cell transplants safer for blood cancer patients?
Disease control Not yet recruitingThis study tests if a lower dose of a drug called cyclophosphamide can reduce side effects after a stem cell transplant from a half-matched donor in people with blood cancers. About 180 adults will be randomly assigned to receive either the standard or a reduced dose. The goal is…
Matched conditions: GVHD - GRAFT-VERSUS-HOST DISEASE
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 15, 2026 11:54 UTC